Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated:  9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated: 9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated:  9/23/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated: 9/23/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Rotterdam,
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Rotterdam,
Click here to add this to my saved trials
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
Status: Enrolling
Updated:  9/23/2015
The Mayo Clinic
mi
from
Rochester, MN
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
Status: Enrolling
Updated: 9/23/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Ottawa,
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Ottawa,
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Hematology Oncology P.C.
mi
from
Stamford, CT
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Hematology Oncology P.C.
mi
from
Stamford, CT
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Mass General Hospital
mi
from
Boston, MA
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Henry Ford Hospital
mi
from
Detroit, MI
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Piedmont Hematology-Oncology Associates
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Oregon Health and Science University
mi
from
Portland, OR
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Hema/Oncology Assoc. Of Nepa
mi
from
Dunmore, PA
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Hema/Oncology Assoc. Of Nepa
mi
from
Dunmore, PA
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Cancer Center of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Bahia Blanca,
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Bahia Blanca,
Click here to add this to my saved trials
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated:  9/23/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated: 9/23/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated:  9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated: 9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Toronto,
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Toronto,
Click here to add this to my saved trials
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Enrolling
Updated:  9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival
Status: Enrolling
Updated: 9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated:  9/23/2015
Michigan State University
mi
from
East Lansing, MI
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Status: Enrolling
Updated: 9/23/2015
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Duarte, CA
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Duarte, CA
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Los Angeles, CA
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Orange, CA
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
San Francisco, CA
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Aurora, CO
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Tucker, GA
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Tucker, GA
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Indianapolis, IN
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
New York, NY
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Cleveland, OH
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Nashville, TN
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Dallas, TX
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  9/24/2015
GSK Investigational Site
mi
from
Camperdown,
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 9/24/2015
GSK Investigational Site
mi
from
Camperdown,
Click here to add this to my saved trials
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors
Status: Enrolling
Updated:  9/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors
Status: Enrolling
Updated: 9/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Hollywood, FL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Orlando, FL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Chicago, IL
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Marrero, LA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Marrero, LA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Metairie, LA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Baltimore, MD
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Boston, MA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Rochester, MN
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Oklahoma City, OK
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Houston, TX
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
Seattle, WA
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  9/24/2015
ImClone Investigational Site
mi
from
London,
Study of Ramucirumab in Ovarian Cancer
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 9/24/2015
ImClone Investigational Site
mi
from
London,
Click here to add this to my saved trials
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Status: Enrolling
Updated:  9/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Status: Enrolling
Updated: 9/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated:  9/25/2015
Clinical Research Facility
mi
from
Orlando, FL
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Status: Enrolling
Updated: 9/25/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials